Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.54 |
| ▸ | HTR2A | P28223 | 9/20 | 0.54 |
| ▸ | DRD2 | P14416 | 6/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6105302 | 0.94 | HTR1A (0.56) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL6104305 | 0.92 | HTR1A (0.54) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL6107977 | 0.87 | HTR1A (0.55) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL6107598 | 0.87 | HTR1A (0.55) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL6105453 | 0.86 | HTR2A (0.53) | HTR2ADRD2 | |
| SCHEMBL6105815 | 0.86 | HTR1A (0.55) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL6107107 | 0.86 | HTR1A (0.56) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL6108056 | 0.85 | HTR1A (0.61) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL6106238 | 0.85 | HTR1A (0.64) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL6105460 | 0.84 | HTR1A (0.57) | HTR1AHTR2ADRD2KCNH2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101886-B2 | Phenylalkyl and pyridylalkyl piperazine derivatives | WARNER LAMBERT COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040186108-A1 | Phenylalkyl and pyridylalkyl piperazine derivatives | CHO STEPHEN SUNG YONG (US) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186108-A1 | Phenylalkyl and pyridylalkyl piperazine derivatives | CNR1, CNR2, PMP22 | HTR1A 23/4885HTR2A 61/4885DRD2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.